Cassava Sciences | PTIE - Selling And Administration Expenses

Stock Price
1.96
Daily Change
0.02 1.03%
Monthly
-6.67%
Yearly
-17.99%
Q1 Forecast
1.93

Cassava Sciences reported $7.9M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
Amgen USD 1.7B 9M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
Cassava Sciences USD 7.9M 1.08M Sep/2025
Eisai JPY 103.86B 3.7B Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Geron USD 39M 437K Sep/2025
J&J USD 6.75B 831M Dec/2025
Merck USD 2.63B 0 Sep/2025
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Roche Holding CHF 7.28B 3.99B Dec/2025